133 related articles for article (PubMed ID: 752870)
21. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
22. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
Hedley DW; McElwain TJ; Currie GA
Br J Cancer; 1978 Apr; 37(4):491-6. PubMed ID: 646922
[TBL] [Abstract][Full Text] [Related]
23. Letter: Chemoimmunotherapy of malignant melanoma.
N Engl J Med; 1975 Jan; 292(3):159-60. PubMed ID: 1196343
[No Abstract] [Full Text] [Related]
24. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
Newlands ES; Oon CJ; Roberts JT; Elliott P; Mould RF; Topham C; Madden FJ; Newton KA; Westbury G
Br J Cancer; 1976 Aug; 34(2):174-9. PubMed ID: 962994
[TBL] [Abstract][Full Text] [Related]
25. [Results of immunochemotherapy in malignant melanoma].
Duchková H; Richter J; Kubíková M; Peska J; Ragan J; Vohryzková E; Hrivnáková J; Kvasnicka J
Cesk Dermatol; 1980 Aug; 55(4):277-80. PubMed ID: 7407970
[No Abstract] [Full Text] [Related]
26. [Adjuvant chemotherapy in malignant melanoma after pretherapeutic sensitivity testing].
Zaumseil RP; Wohlrab W; Fiedler H; Wozniak KD
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):721-4. PubMed ID: 6172340
[No Abstract] [Full Text] [Related]
27. Combined modality therapy of malignant melanoma.
Hersh EM; Gutterman JU; McBride CM
World J Surg; 1979 Jul; 3(3):329-43. PubMed ID: 382647
[No Abstract] [Full Text] [Related]
28. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
Hedley DW; McElwain TJ; Currie GA
Eur J Cancer (1965); 1977 Oct; 13(10):1169-73. PubMed ID: 923614
[No Abstract] [Full Text] [Related]
29. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
30. [5-year results of a chemo-immunotherapeutic treatment in stage-I and -II malignant melanoma].
Comella G; Mastro AA; Comella P; Castello G; De Simone G; Cerra R; Zarrilli D
Minerva Med; 1986 Mar; 77(13):507-10. PubMed ID: 3703343
[No Abstract] [Full Text] [Related]
31. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG.
Karakousis CP; Emrich LJ
J Surg Oncol; 1987 Dec; 36(4):235-8. PubMed ID: 3695527
[TBL] [Abstract][Full Text] [Related]
32. Results of a nonrandomized trial in malignant melanoma patients (Clark's stages III--V) treated by post-surgical chemoimmunotherapy.
Serrou B; Pujol H; Domas J; Gauci L
Recent Results Cancer Res; 1978; 68():363-6. PubMed ID: 752871
[No Abstract] [Full Text] [Related]
33. Results of administering B.C.G. to patients with melanoma.
Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
[No Abstract] [Full Text] [Related]
34. Surgical adjuvant therapy for malignant melanoma.
Pinsky CM; Oettgen HF
Surg Clin North Am; 1981 Dec; 61(6):1259-66. PubMed ID: 7031933
[No Abstract] [Full Text] [Related]
35. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
[TBL] [Abstract][Full Text] [Related]
36. Malignant melanoma (stage IIIB): a pilot study of adjuvant chemo-immunotherapy.
Paterson AH; McPherson TA; Willans DJ
Cancer Treat Rep; 1978 Apr; 62(4):571-3. PubMed ID: 350395
[No Abstract] [Full Text] [Related]
37. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
[TBL] [Abstract][Full Text] [Related]
38. [Immunological aspects in the treatment of malignant melanoma].
Cascinelli N; Vaglini M; Rovini D; Orefice S; Marolda R; Veronesi U
Minerva Med; 1982 Apr; 73(18):1233-40. PubMed ID: 7078802
[No Abstract] [Full Text] [Related]
39. Management of recurrent melanoma of the extremity.
Shingleton WW; Seigler HF; Stocks LH; Downs RW
Cancer; 1975 Mar; 35(3):574-9. PubMed ID: 234293
[TBL] [Abstract][Full Text] [Related]
40. Inconsistent response of B16 melanoma to BCG immunotherapy.
Kreider JW; Bartlett GL; Purnell DM
J Natl Cancer Inst; 1976 Apr; 56(4):803-10. PubMed ID: 1255799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
